Consensus Natera, Inc.

Stocks

NTRA

US6323071042

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 16:36:44 13/07/2026 BST			5-day change	1st Jan Change
269.82 ^USD	-0.05%		-5.19%	+17.45%

07-09	Natera Receives EU IVDR Certification for Signatera	MT
07-06	Natera, Inc. Announces Resignation of Monica Bertagnolli as A Member of the Board and Any Committees of the Board, Effective July 1, 2026	CI

Evolution of the Average Target: Natera, Inc.

Evolution of the Target Price: Natera, Inc.

Changes in Analyst Recommendations: Natera, Inc.

3a76cecf9849062d81461.9KdDoSXmf4ioUGI-5Sl0-IWNPoaQZswdE93AhcLoO6U.oM41ym3VLr-ZI1tRjm01odDIUcDdP4FoWaix9rabcPG_xRrYfKo13-kpUg~d68ba68d2343a9533afb8a76e7cb52cf

Analysts' recommendations: Natera, Inc.

10:34am	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
06-12	Natera MRD Leadership Supported by 'Durable' High-Value Market, RBC Says	MT
04-14	William Blair Initiates Natera at Outperform	MT
03-03	Morgan Stanley Cuts Price Target on Natera to $250 From $265, Keeps Overweight Rating	MT
02-27	UBS Adjusts Natera Price Target to $290 From $280, Maintains Buy Rating	MT
01-07	Citigroup Initiates Natera at Buy With $300 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Natera to $265 From $220, Keeps Overweight Rating	MT
11-18	UBS Adjusts Natera Price Target to $280 From $218, Maintains Buy Rating	MT
11-14	Analyst recommendations: Applied Materials, The Gap, Home Depot, Abercrombie & Fitch…
11-07	America's markets lose their nerve
11-07	Analyst recommendations: AMD, Carmax, Datadog, Instacart, SanDisk…
12/10/25	Natera says to present 14 studies at Esmo, including Imvigor011 oral presentation	RE
03/09/25	RBC Raises Price Target on Natera to $268 From $255, Keeps Outperform Rating	MT
08/08/25	RBC Raises Price Target on Natera to $255 From $251, Keeps Outperform Rating	MT
13/03/25	RBC Initiates Natera at Outperform With $251 Price Target	MT
05/03/25	Morgan Stanley Raises Price Target on Natera to $185 From $176, Keeps Overweight Rating	MT
28/02/25	UBS Raises Price Target on Natera to $211 From $209, Keeps Buy Rating	MT
23/01/25	Barclays Initiates Natera at Overweight	MT
19/11/24	UBS Adjusts Price Target on Natera to $209 From $145, Maintains Buy Rating	MT
13/11/24	Morgan Stanley Adjusts Natera Price Target to $176 From $132, Maintains Overweight Rating	MT
13/08/24	Natera's H2 Guidance Leaves 'Ample Room' for Upside, Morgan Stanley Says	MT
13/08/24	Morgan Stanley Adjusts Natera's PT to $132 From $125, Keeps Overweight Rating	MT
13/08/24	Analyst recommendations: Dell, Palo Alto Networks, Snowflake, Warner Bros, Stellantis...
09/08/24	UBS Adjusts Price Target on Natera to $145 From $160, Maintains Buy Rating	MT
09/08/24	UBS Cuts Price Target on Natera to $145 From $160, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NATERA, INC.					+0.48%
	LABCORP HOLDINGS INC.					+12.35%
	SONIC HEALTHCARE LIMITED					+13.62%
	RADNET, INC.					+36.81%
	DR. LAL PATHLABS LIMITED					+1.25%
	GENEDX HOLDINGS CORP.					+19.51%
	DIAN DIAGNOSTICS GROUP CO.,LTD.					-7.9%
	NEOGENOMICS, INC.					+7.1%
	FLEURY S.A.					+5.46%
	GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.					+23.83%
	Average					+11.25%
	Weighted average by Cap.					+7.90%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

269.95USD

Average target price

271.24USD

Spread / Average Target

+0.48%

High Price Target

325.00USD

Spread / Highest target

+20.39%

Low Price Target

193.00USD

Spread / Lowest Target

-28.51%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

William Blair & Co.
Morgan Stanley
UBS
Citigroup
RBC Capital Markets
Barclays
Jefferies & Co.
Piper Sandler
BTIG
Baird
Goldman Sachs
Bernstein
Canaccord Genuity
Raymond James
TD Cowen
Credit Suisse
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Craig-Hallum
SVB Leerink
Truist Securities